Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.
Development
Latest News
Advertisement
Research into Cold Cancers Heating Up
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Proprietary Cell-Line Development for High-Titer AAV Manufacturing
Proprietary cell lines offer opportunities for achieving high AAV titers.
Bracing for a Future Wave of Advanced Therapies
In the ATMP space, CGTs are hitting their stride with unprecedented approvals in the past year alone.
Advertisement
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under development for cancer treatment.
Best Practices, Strategies & Utilization of Novel Biological Responses for Robust Cell-Based Potency Assays
ByCatalent
Webcasts
Webinar Date/Time: Wed, Feb 28, 2024 11:00 AM EST
Regulators from around the world will gather to help shape the mRNA and RNA therapeutics landscape at an exceptional April 2024 Washington, D.C. convocation.
Webcasts
Webinar Date/Time: Thu, Feb 8, 2024 11:00 AM EST
In a deal worth up to $1.4 billion, GSK aims to acquire Aiolos Bio and gain an expanded pipeline of biologic-based respiratory therapeutic candidates.
MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.
Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.
The new Europe headquarters will be the hub for the company’s European operations, including production of product.
The authors give an overview of scaling approaches and present good scaling practices for the biopharma industry.
The success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.
Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.
Under a collaboration, Daiichi Sankyo and Depixus will use Depixus’ MAGNA technology to accelerate drug discovery efforts of RNA-targeted therapeutics.
Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.
Creating a Closed Process Semi-Automated Workflow for Human MSC Expansion, Harvest, and Final Fill.
ByEntegris
Webcasts
Webinar Date/Time: Thu, Jan 25, 2024 11:00 AM EST
The new advisory committee will provide the agency with technical and scientific advice and recommendations on potential treatments for genetic metabolic diseases.
A look at how linker technology for antibody drug conjugates has evolved.
AstraZeneca will utilize Absci’s AI antibody drug creation platform to create an AI-designed antibody.
Biologics have specific quality considerations that make fast tracking these drugs more difficult.
Preparing for variability and flexible processing are necessary for success.
Exagamglogene autotemcel seen as synechdoche.
Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.
In part two of an interview with Thomas Langenickel, MD, chief medical officer at Ethris, Langenickel highlights the challenges in developing mRNA therapeutics for pulmonary diseases.
Advertisement
Advertisement